Medios stock gains 1.10 percent as 2031 plan targets EUR 3.1 billion

Published on 09/30/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medios stock carries Deutsche Bank's Buy rating and EUR 16.00 target dated September 30, 2026. H1 2026 leverage was 1.32 times EBITDA against a 2.0 times ceiling.

Moderne Pharma-Lagerhalle mit Mitarbeiter im Kittel und gekühlten Medikamentenschränken — Medios AG (DE000A1MMCC8) beliefert Apotheken über ein modernes Pharma-Großhandelslager mit Kühlzonen und Logistik, Illustration mit AI erstellt.

Medios stock (ISIN DE000A1MMCC8) was trading at EUR 11.03 at Lang & Schwarz on September 30, 2026 at 12:35 p.m. CEST, up 1.10 percent from the prior close of EUR 10.91. The company presented a 2031 strategy on September 29 that targets materially higher revenue and adjusted EBITDA.

2031 plan targets EUR 3.1 billion

According to EQS News on September 29, 2026, Medios aims to reach EUR 3.1 billion in revenue by 2031. That target is presented as 50 percent above the EUR 2.1 billion revenue base reported for 2025.

The strategy shifts Medios toward a Pharma Services model built around Specialty Pharma Supply and Compounding. The company expects Compounding to contribute disproportionately to earnings because its margin profile is higher than that of the supply business.

Adjusted EBITDA target doubles

Medios sets adjusted EBITDA at EUR 170 million for 2031, compared with EUR 87 million under the new definition for 2025. The 2025 baseline carried a 4.2 percent adjusted EBITDA margin, while the 2031 group ambition is a 5.5 percent margin.

The balance-sheet target adds a measurable constraint to the expansion plan. Net debt to EBITDA stood at 1.32 times in the first half of 2026, against an internal ceiling of 2.0 times, according to EQS News. That leaves 0.68 times of stated headroom before the internal limit, although the company also identifies selective acquisitions as a growth tool.

Deutsche Bank keeps EUR 16 target

finanzen.ch reported on September 30, 2026 that Deutsche Bank Research retained its Buy rating and EUR 16.00 price target after the Capital Markets Day. The assessment gives the strategy a direct valuation test: execution must convert the revenue plan into the targeted earnings mix.

For investors, the central issue is the quality of that conversion rather than revenue growth alone. Medios expects Compounding to improve margins, while Specialty Pharma Supply remains the cash-generative segment that supports the group's operating base.

Medios stock trades at EUR 11.03

At Lang & Schwarz, Medios stock was trading at EUR 11.03 on September 30, 2026 at 12:35 p.m. CEST, up 1.10 percent versus the Lang & Schwarz prior close of EUR 10.91 on September 29, 2026.